{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:35Z","timestamp":1792612895321,"version":"4.5.0"},"reference-count":85,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare and aggressive non-Hodgkin\u2019s lymphomas. Clinical staging, prognostic scoring, and initial treatment strategies have historically been based on paradigms developed in B-cell lymphomas. Despite primary treatment protocols that are typically anthracycline-based and frequently involve consolidative autologous stem cell transplantation in first remission, many patients develop disease progression. There remains a high unmet medical need for improved treatment strategies in the relapsed or refractory setting. Salvage chemotherapy and stem cell transplantation in those who are suitable has traditionally been the accepted approach, but this remains a minority of the total patient population. As increasing knowledge is gleaned regarding the biological heterogeneity within the various PTCL subtypes, newer targeted agents have been developed, studied, and approved in this small, heterogeneous population of relapsed or refractory disease. Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL. As others undergo further development in the relapsed setting and successes are brought earlier in the disease course, the outcome for PTCL patients is likely to improve. However, innovative clinical trial designs are crucial for the assessment of targeted agents in this highly heterogeneous population. This review explores the current treatment environment for patients with relapsed and refractory PTCL, including newer strategies such as targeted agents and immunotherapy.<\/ns4:p>","DOI":"10.12688\/f1000research.22257.1","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T09:00:05Z","timestamp":1599210005000},"page":"1091","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment approaches in relapsed or refractory peripheral T-cell lymphomas"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-8482","authenticated-orcid":false,"given":"Cheryl","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"4124-30","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes.","volume":"26","author":"J Vose","year":"2008","journal-title":"J Clin Oncol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"3418-25","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.","volume":"116","author":"N Schmitz","year":"2010","journal-title":"Blood."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"3664-70","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.","volume":"115","author":"M Sieniawski","year":"2010","journal-title":"Blood."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"465-8","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: A UK NCRI\/Cancer Research UK Phase II Study.","volume":"54","author":"E Phillips","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"229-40","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial.","volume":"393","author":"S Horwitz","year":"2019","journal-title":"Lancet."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/blood-2019-122781","article-title":"An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant.","volume":"134","author":"K Savage","year":"2019","journal-title":"Blood."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"147-51","DOI":"10.1002\/hon.2144","article-title":"Dismal outcome of T-cell lymphoma patients failing first-line treatment: Results of a population-based study from the Modena Cancer Registry.","volume":"33","author":"I Biasoli","year":"2015","journal-title":"Hematol Oncol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1970-6","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors.","volume":"31","author":"V Mak","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"750-8","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.","volume":"176","author":"D Chihara","year":"2017","journal-title":"Br J Haematol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1191-7","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective, International T-Cell Project.","volume":"103","author":"M Bellei","year":"2018","journal-title":"Haematologica."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"3048-58","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group.","volume":"32","author":"S Barrington","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"3059-67","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.","volume":"32","author":"B Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"589-95","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.","volume":"59","author":"A Cottereau","year":"2018","journal-title":"J Nucl Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"975-80","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients.","volume":"90","author":"T El-Galaly","year":"2015","journal-title":"Am J Hematol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"687-91","DOI":"10.1016\/j.clml.2018.06.022","article-title":"Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma.","volume":"18","author":"R Gurion","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","article-title":"Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.","volume":"15","author":"S Jung","year":"2015","journal-title":"BMC Cancer."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"256-9","DOI":"10.3109\/10428194.2014.914194","article-title":"Prognostic significance of 18Ffluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: A retrospective analysis.","volume":"56","author":"L Shea","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"2474-9","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study.","volume":"103","author":"A Gallamini","year":"2004","journal-title":"Blood."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2319-27","DOI":"10.1080\/10428194.2017.1312379","article-title":"Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: A subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.","volume":"58","author":"T Skamene","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1845-51","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: A consortium for improving survival of lymphoma (CISL) trial.","volume":"94","author":"B Park","year":"2015","journal-title":"Ann Hematol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"989-94","DOI":"10.1007\/s00277-015-2309-z","article-title":"Modified ESHAP regimen for relapsed\/refractory T cell lymphoma: A retrospective analysis.","volume":"94","author":"Y Kogure","year":"2015","journal-title":"Ann Hematol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"i5-10","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.","volume":"14 Suppl 1","author":"A Zelenetz","year":"2003","journal-title":"Ann Oncol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"e0161811","DOI":"10.1371\/journal.pone.0161811","article-title":"Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.","volume":"11","author":"Y Yang","year":"2016","journal-title":"PLoS One."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"641-9","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.","volume":"94","author":"R Stuver","year":"2019","journal-title":"Am J Hematol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1826-38","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.","volume":"23","author":"M Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"443-50","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study.","volume":"40","author":"S Feyler","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"405-10","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nation-wide survey.","volume":"33","author":"E Jantunen","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"507-13","DOI":"10.3109\/10428194.2012.719615","article-title":"Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.","volume":"54","author":"N Puig","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1067-74","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma.","volume":"92","author":"J Rodr\u00edguez","year":"2007","journal-title":"Haematologica."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"978-85","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological subtype.","volume":"120","author":"K Song","year":"2003","journal-title":"Br J Haematol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"3100-9","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.","volume":"31","author":"S Smith","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"741-7","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience.","volume":"14","author":"A Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1540-5","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.","volume":"333","author":"T Philip","year":"1995","journal-title":"N Engl J Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"802-14","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed\/Refractory Setting: A Systematic Review\/Meta-Analysis.","volume":"22","author":"J El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"245-53","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.","volume":"132","author":"N Schmitz","year":"2018","journal-title":"Blood."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1182-9","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study.","volume":"29","author":"O O'Connor","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"2061-8","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.","volume":"108","author":"D Maruyama","year":"2017","journal-title":"Cancer Sci."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"149-58","DOI":"10.1007\/s11523-019-00630-y","article-title":"Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.","volume":"14","author":"X Hong","year":"2019","journal-title":"Target Oncol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"pky038","DOI":"10.1093\/jncics\/pky038","article-title":"Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study.","volume":"2","author":"O O'Connor","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses.","volume":"7","author":"B Coiffier","year":"2014","journal-title":"J Hematol Oncol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"5827-34","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.","volume":"117","author":"R Piekarz","year":"2011","journal-title":"Blood."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2492-9","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.","volume":"33","author":"O O'Connor","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1766-71","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.","volume":"26","author":"Y Shi","year":"2015","journal-title":"Ann Oncol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2709-17","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.","volume":"130","author":"B Pro","year":"2017","journal-title":"Blood."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.","volume":"7","author":"N Bartlett","year":"2014","journal-title":"J Hematol Oncol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"613-23","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.","volume":"37","author":"O O'Connor","year":"2019","journal-title":"J Clin Oncol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase\u2013Positive Lymphoma Patients.","volume":"106","author":"C Passerini","year":"2014","journal-title":"J Natl Cancer Inst."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"888-98","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.","volume":"131","author":"S Horwitz","year":"2018","journal-title":"Blood."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"877-87","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies.","volume":"131","author":"I Flinn","year":"2018","journal-title":"Blood."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood-2019-121401","article-title":"Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase.","volume":"134","author":"S Horwitz","year":"2019","journal-title":"Blood."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1157-63","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.","volume":"32","author":"M Ogura","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"993-1003","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma.","volume":"104","author":"A Phillips","year":"2019","journal-title":"Haematologica."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"e407-e410","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma.","volume":"101","author":"P Zinzani","year":"2016","journal-title":"Haematologica."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"2190-6","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study.","volume":"30","author":"B Pro","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"2698-704","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.","volume":"34","author":"A Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"356-364.e3","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.","volume":"19","author":"S Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"121-5","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.","volume":"552","author":"T Wartewig","year":"2017","journal-title":"Nature."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1947-8","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.","volume":"378","author":"L Ratner","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"397-407","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.","volume":"131","author":"J Amengual","year":"2018","journal-title":"Blood."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts.","volume":"132","author":"S Horwitz","year":"2018","journal-title":"Blood."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1160-3","DOI":"10.3346\/jkms.2016.31.7.1160","article-title":"Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.","volume":"31","author":"S Lee","year":"2016","journal-title":"J Korean Med Sci."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).","volume":"134","author":"S Iyer","year":"2019","journal-title":"Blood."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"1156-66","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.","volume":"23","author":"C Wang","year":"2017","journal-title":"Clin Cancer Res."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"3462-71","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes.","volume":"127","author":"C Ramos","year":"2017","journal-title":"J Clin Invest."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.bbmt.2018.12.149","article-title":"A Phase Ib\/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed\/Refractory CD30+ Lymphomas.","volume":"25","author":"N Grover","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed\/Refractory T-Cell Malignancies.","volume":"134","author":"L Hill","year":"2019","journal-title":"Blood."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving CD30-directed CAR-T cells to the clinic.","volume":"19","author":"N Grover","year":"2019","journal-title":"BMC Cancer."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"1416-23","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies.","volume":"23","author":"P Maciocia","year":"2017","journal-title":"Nat Med."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"5496-504","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project.","volume":"111","author":"K Savage","year":"2008","journal-title":"Blood."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"1473-80","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.","volume":"124","author":"E Parrilla Castellar","year":"2014","journal-title":"Blood."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"e28-e31","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.","volume":"186","author":"G Hapgood","year":"2019","journal-title":"Br J Haematol."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"36-43","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.","volume":"40","author":"R King","year":"2016","journal-title":"Am J Surg Pathol."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"2375-90","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"S Swerdlow","year":"2016","journal-title":"Blood."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"1466-9","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.","volume":"120","author":"F Lemonnier","year":"2012","journal-title":"Blood."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"171-5","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"1901-3","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.","volume":"119","author":"R Cairns","year":"2012","journal-title":"Blood."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"223-32","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study.","volume":"10","author":"P Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"2386-98","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.","volume":"378","author":"C DiNardo","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"722-31","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.","volume":"130","author":"E Stein","year":"2017","journal-title":"Blood."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"913-6","DOI":"10.1111\/bjh.13170","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.","volume":"168","author":"M Cheminant","year":"2015","journal-title":"Br J Haematol."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"2305-9","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.","volume":"132","author":"F Lemonnier","year":"2018","journal-title":"Blood."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"864-8","DOI":"10.1002\/hon.2319","article-title":"Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.","volume":"35","author":"C Saillard","year":"2017","journal-title":"Hematol Oncol."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"3316-9","DOI":"10.1080\/10428194.2019.1627541","article-title":"Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.","volume":"60","author":"M Tobiasson","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"1395-405","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study.","volume":"134","author":"O O\u2019Connor","year":"2019","journal-title":"Blood."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"2915-23","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.","volume":"123","author":"J Iqbal","year":"2014","journal-title":"Blood."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T09:05:26Z","timestamp":1599210326000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":85,"URL":"https:\/\/doi.org\/10.12688\/f1000research.22257.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.24551.r70386","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.24551.r70385","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.24551.r70387","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.24551.r70385, H. Miles Prince, Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia, 04 Sep 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1#referee-response-70385","order":0,"name":"referee-response-70385","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.24551.r70386, Matthew J. Ahearne, Leicester Cancer Research Centre, Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, UK, 04 Sep 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1#referee-response-70386","order":1,"name":"referee-response-70386","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.24551.r70387, Barbara Pro, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA, 04 Sep 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1091\/v1#referee-response-70387","order":2,"name":"referee-response-70387","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}